128 related articles for article (PubMed ID: 35304777)
21. [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas].
He Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):505-510. PubMed ID: 28655094
[No Abstract] [Full Text] [Related]
22. SUV39H1 is a prognosis and immune microenvironment-related biomarker in diffuse large B-cell lymphoma.
Zhang Y; Qian S; Wen Q; Lei Y; Ge J; Kong X; Wang W; Wang Z; Hou H; Tang C; Wu S; Wang G; Li W; Zhang M; Zhang X; Chen Q
Clin Transl Oncol; 2023 Aug; 25(8):2438-2450. PubMed ID: 37029239
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count.
Li YL; Shi ZH; Wang X; Gu KS; Zhai ZM
BMC Cancer; 2019 Nov; 19(1):1049. PubMed ID: 31694577
[TBL] [Abstract][Full Text] [Related]
24. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
25. The prevalence and function of CD4
Cha Z; Gu H; Zang Y; Wang Z; Li J; Huang W; Qin A; Zhu L; Tu X; Cheng N; Song H; Qian B
Int Immunopharmacol; 2018 Aug; 61():132-139. PubMed ID: 29870918
[TBL] [Abstract][Full Text] [Related]
26. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.
Ansell SM; Maurer MJ; Ziesmer SC; Slager SL; Habermann TM; Link BK; Witzig TE; Macon WR; Dogan A; Cerhan JR; Novak AJ
Am J Hematol; 2012 Sep; 87(9):865-9. PubMed ID: 22674570
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
28. CCL8 as a promising prognostic factor in diffuse large B-cell lymphoma
Lou X; Zhao K; Xu J; Shuai L; Niu H; Cao Z; Wang J; Zhang Y
Front Immunol; 2022; 13():950213. PubMed ID: 36072582
[TBL] [Abstract][Full Text] [Related]
29. Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.
Stirm K; Leary P; Bertram K; Núñez NG; Wüst D; Boudesco C; Verhoeyen E; Zenz T; Becher B; Menter T; Tzankov A; Müller A
Oncoimmunology; 2021; 10(1):2003533. PubMed ID: 34858727
[TBL] [Abstract][Full Text] [Related]
30. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
[TBL] [Abstract][Full Text] [Related]
31. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
Nam SJ; Go H; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Leuk Lymphoma; 2014 Nov; 55(11):2466-76. PubMed ID: 24397616
[TBL] [Abstract][Full Text] [Related]
32. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
33. CXCR5
Tang J; Zha J; Guo X; Shi P; Xu B
Int Immunopharmacol; 2017 Sep; 50():146-151. PubMed ID: 28662433
[TBL] [Abstract][Full Text] [Related]
34. Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and
Hui Z; Zhang J; Zheng Y; Yang L; Yu W; An Y; Wei F; Ren X
Front Immunol; 2021; 12():619932. PubMed ID: 33868236
[TBL] [Abstract][Full Text] [Related]
35. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cells.
Sun R; Zhang PP; Weng XQ; Gao XD; Huang CX; Wang L; Hu XX; Xu PP; Cheng L; Jiang L; Fu D; Qu B; Zhao Y; Feng Y; Dou HJ; Zheng Z; Zhao WL
Signal Transduct Target Ther; 2022 Mar; 7(1):80. PubMed ID: 35301282
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
[TBL] [Abstract][Full Text] [Related]
39. Presence of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma.
Cao Y; Liu Z; Wu W; Qian Y; Shi Q; Shen R; Ouyang B; Xu P; Cheng S; Ye J; Lu Y; Wang C; Yang C; Wang L; Zhao W
Front Med; 2019 Feb; 13(1):94-103. PubMed ID: 30706260
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis.
Fan L; Lin Q; Huang X; Fu D; Huang H
BMC Cancer; 2021 Nov; 21(1):1255. PubMed ID: 34802440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
